Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors FREDERICK, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the appointment of Adrian Bot, M.D., Ph.D., to the Company’s Board of Directors. Dr. Bot is a biopharma executive with three decades of experience in research and development (R&D) with a focus on immune, cell, gene therapy and nanomedicines. He will serve as a member of the Science and Technol...
SAIC Appoints Ravi Dankanikote as New Chief Growth Officer RESTON, Va., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Science Applications International Corporation (NASDAQ: ), a premier Fortune 500® company driving our nation's digital transformation across the defense, space, intelligence, and civilian markets, today announced the appointment of Ravi Dankanikote as the company’s Chief Growth Officer, effective immediately. He will report to Interim SAIC Chief Executive Officer Jim Reagan. In this role, Dankanikote will lead SAIC’s enterprise growth strategy and go-to-market approach. He brings mor...
Oak Valley Community Bank Welcomes Dan Greene as Vice President, Branch Manager of Tracy Branch OAKDALE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Oak Valley Community Bank, a wholly-owned subsidiary of Oak Valley Bancorp (NASDAQ: OVLY), is pleased to welcome Dan Greene as Vice President, Branch Manager. Greene will oversee the bank’s Tracy branch at 1034 North Central Avenue, where he will guide operational strategy, nurture client relationships, and promote growth through a strong focus on service excellence. His responsibilities will also include supporting the financial needs of local...
SAIC Announces Third Quarter of Fiscal Year 2026 Results Revenues of $1.87 billionNet bookings of $2.2 billion; book-to-bill ratio and trailing twelve months book-to-bill ratio of 1.2Year-to-date net bookings of $7.2 billion; year-to-date book-to-bill ratio of 1.3Net income of $78 million; Adjusted EBITDA(1) of $185 million or 9.9% of revenuesDiluted earnings per share of $1.69; Adjusted diluted earnings per share(1) of $2.58Cash flows provided by operating activities of $129 million; Free cash flow(1) of $135 millionCompany increases fiscal year 2026 guidance on certain key metrics RESTON...
U.S. Navy Awards SAIC $242M Contract to Operate, Maintain and Upgrade Propulsion Test Facility Contract enables essential operations of Navy’s premiere undersea weapon facility, including testing & production of Mk 48, Mk 45, UUV, sensors and more RESTON, Va., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Science Applications International Corp. (NASDAQ: ) has been awarded a $242 million contract by the Naval Undersea Warfare Center Division, Newport (NUWCDIVNPT) to enable the continued operation, maintenance and modernization of the Propulsion Test Facility (PTF), in support of the Undersea Warfar...
SAIC Schedules Third Quarter Fiscal Year 2026 Earnings Conference Call for December 4 at 10 A.M. ET RESTON, Va., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Science Applications International Corp. (NASDAQ: ) is scheduled to issue its third quarter fiscal year 2026 results before market open on Thursday, December 4, 2025. SAIC executive management will discuss operational and financial results in a conference call beginning at 10:00 a.m. Eastern time, following the issuance of the company’s earnings press release. The conference call will be webcast simultaneously to the public through a link o...
SAIC Secures $1.4 Billion COBRA Task Order to Fast-Track Warfighting Technologies from Concept to Combat Mission integrator will rapidly deliver next-gen capabilities that accelerate decision superiority, strengthen readiness and enhance lethality RESTON, Va., Nov. 20, 2025 (GLOBE NEWSWIRE) -- America’s leading mission integrator, Science Applications International Corp. (NASDAQ: ), has been awarded the $1.4 billion COBRA (Collaborative Operations for Battlespace Resilient Architecture) task order in support of the Department of War (DoW). COBRA will leverage SAIC’s expertise in command...
SAIC and HavocAI Partner to Link Autonomous Fleets to Global Command and Control Infrastructure for U.S. Navy RESTON, Va., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Science Applications International Corp. (NASDAQ: ), a premier Fortune 500 mission integrator, and HavocAI, the leader in collaborative maritime autonomy, today announced an effort to integrate SAIC’s real-time, multi-domain communications and data backbone with HavocAI's fully-autonomous, problem-solving fleets. This collaboration will drastically improve maritime domain awareness within the joint, unified warfighting network for the...
SAIC Announces Organizational Changes Intended to Simplify Structure, Sharpen Focus and Deliver Sustainable Long-Term Growth and Shareholder Value Creation Highlights: Five existing business groups will be consolidated into three business groupsThe consolidated business groups are Army Navy (ANG); Air Force, Space and Intelligence (AFSI); and Civilian The restructured organization is aimed at optimizing the company’s operations and customer focus for growth and shareholder value creationThe new organizational structure will be effective January 31, 2026 RESTON, Va., Nov. 13, 2025 (GLOBE...
Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis 100% LLDAS response rate observed in patients with SLE who received Descartes-08 in Phase 2 open-label trial reaching Month 3 follow-up (n=3) Disease remission reported as DORIS response seen in 2 out of 3 patients reaching Month 3 follow-up (n=3) Descartes-08 in SLE patients was observed to have a favorable safety profile supporting outpatient administration without the need for lymphodepleting chemotherapy Myositis seamless a...
Cartesian Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Preliminary data from Phase 2 trial of Descartes-08 in systemic lupus erythematosus expected by end of year Initiation of Phase 2 pediatric basket trial of Descartes-08 in select autoimmune indications expected by end of year Approximately $145.1 million cash, cash equivalents and restricted cash as of September 30, 2025, expected to support planned operations into mid-2027, including completion of ongoing Phas...
Oak Valley Community Bank Receives Approval to Award City Ministry Network a $150,000 Grant Supporting Workforce Development OAKDALE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Oak Valley Community Bank, a wholly-owned subsidiary of Oak Valley Bancorp (NASDAQ: OVLY), announced they have received approval on a 2025 AHEAD grant of $150,000, which was submitted to the Federal Home Loan Bank of San Francisco (FHLBank San Francisco) on behalf of City Ministry Network. Communities across Stanislaus and San Joaquin Counties are set to see expanded workforce opportunities for Latino youth. This i...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.